U.S. stock futures were mixed this morning, with the Nasdaq 100 futures gaining around 100 points on Tuesday.

Shares of Telefonaktiebolaget LM Ericsson – ADR (NASDAQ:ERIC) fell sharply in pre-market trading following second-quarter results.

ERIC reported quarterly earnings of 13 cents per share which met the analyst consensus estimate. The company reported quarterly sales of $5.422 billion which missed the analyst consensus estimate of $5.840 billion.

Telefonaktiebolaget LM Ericsson shares dipped 9.2% to $10.64  in pre-market trading.

Here are some other stocks moving lower in pre-market trading.

  • Evotec SE (NASDAQ:EVO) shares dipped 18.1% to $1.99 in pre-market trading after declining around 13% on Monday. Evotec announced preliminary second-quarter financial results and updated its full-year 2026 outlook.
  • Braiin Ltd (NASDAQ:BRAI) shares dipped 7.8% to $5.93 in pre-market trading. Braiin shares jumped over 16% on Monday after the company announced the release of ARIA.
  • Perspective Therapeutics Inc (NYSE:CATX) fell 7.4% to $2.86 in pre-market trading.
  • Vicore Pharma Holding AB ADR (NASDAQ:VCRE) declined 6.7% to $11.80 in pre-market trading.
  • Q32 Bio Inc (NASDAQ:QTTB) fell 6.5% to $19.99 in pre-market trading after announcing a proposed public offering of common stock and pre-funded warrants.
  • Kingsoft Cloud Holdings Ltd (NASDAQ:KC) declined 6.2% to $9.75 in pre-market trading after falling around 5% on Monday.
  • Penguin Solutions Inc (NASDAQ:PENG) fell 5% to $73.33 in pre-market trading after the company announced a proposed convertible notes offering.
  • Chagee Holdings Ltd (NASDAQ:CHA) declined 5% to $11.09 in pre-market trading after gaining over 6% on Monday.
  • Baidu Inc (NASDAQ:BIDU) fell 4.2% to $108.59 in pre-market trading following a 4% decline on Monday.
  • SL Science Holding Ltd (NASDAQ:SLBT) slipped 4.1% to $4.15 in pre-market trading after declining over 8% on Monday. SL Science Holding, last week, announced it has submitted an Orphan Drug Designation request to the FDA for its Gamma Delta T cell therapy product, Vdelta2+ Gamma Delta T Cells, for the treatment of glioblastoma multiforme.

Photo via Shutterstock